Kelly Bilodeau's profile photo

Kelly Bilodeau

Boston

Writer at Freelance

Mom, wife, freelance writer.

Featured in: Favicon washingtonpost.com Favicon harvard.edu Favicon madison.com Favicon stltoday.com Favicon tucson.com Favicon cmswire.com Favicon napavalleyregister.com Favicon omaha.com Favicon tulsaworld.com Favicon buffalonews.com

Articles

  • COVID’s remaining biotech contenders navigate a dwindling market

    5 days ago | pharmavoice.com | Kelly Bilodeau

    This audio is auto-generated. Please let us know if you have feedback. Pharma’s sharply declining COVID-19 market is now grappling with a controversial new policy shift. Last week, HHS Secretary Robert F. Kennedy Jr. announced that the CDC would no longer recommend COVID vaccines for healthy children or pregnant women. Instead, the FDA issued updated guidance prioritizing shots for elderly people or those with health problems.

  • Tracking a moving target: How drugmakers should brace for a looming tariff impact

    2 weeks ago | pharmavoice.com | Kelly Bilodeau

    This audio is auto-generated. Please let us know if you have feedback. The threat of tariffs looms over the pharma industry, and drugmakers are looking for ways to be vigilant and nimble in response to potential changes. While the Trump administration exempted pharmaceuticals from reciprocal tariffs announced in early April, it was far from a guarantee that they’d forever be outside the crosshairs.

  • Lupus R&D has come a long way, and the next breakthroughs could come from cell therapy

    3 weeks ago | pharmavoice.com | Kelly Bilodeau

    This audio is auto-generated. Please let us know if you have feedback. When the Lupus Research Alliance formed in 1999, treatment options for the condition were scarce. Doctors relied on a selection of repurposed drugs, antimalarials, steroids and chemotherapies to slow the inflammatory autoimmune disease, said Albert Roy, CEO and president of the LRA and its clinical research affiliate, Lupus Therapeutics. Now, game-changing cell therapy treatments may be around the corner.

  • After an up and down year, pharma’s R&D landscape is shifting again

    1 month ago | pharmavoice.com | Kelly Bilodeau

    This audio is auto-generated. Please let us know if you have feedback. After facing market headwinds in recent years, the biopharma industry finally had some wind at its back in 2024. Jumps in funding and R&D expenditures as well as a continued shift in innovation toward emerging biopharma companies helped fuel the resurgence, according to a new report from the IQVIA Institute for Human Data Science.

  • Will Cobenfy’s clinical stumble derail a once-predicted rise?

    1 month ago | pharmavoice.com | Kelly Bilodeau

    This audio is auto-generated. Please let us know if you have feedback. Bristol Myers Squibb’s schizophrenia drug Cobenfy brought in $27 million in net sales in the first three months of the year — beating Wall Street sales expectations and analyst predictions. Still, its strong debut doesn’t erase uncertainty around the drug, which just stumbled in the clinic, as BMS looks to answer high-stakes questions about its long-term market potential.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
189
Tweets
328
DMs Open
No
No Tweets found.